Sign in
ELVN Stock Price, Chart, Stats & News
Enliven Therapeutics Inc.
Save
3.39B
Market cap
–
Current P/E
–
Forward P/E
ELVN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.78% |
ROE | -24.22% |
D/E | 0.00x |
Interest coverage ratio | – |
ELVN valuation
P/E | – |
P/S | – |
P/B | 4.79x |
P/CF | -31.30x |
P/FCF | -32.96x |
P/OCF | -31.30x |
PEG | -39.04x |
EV multiple | -21.15x |
About
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene.
Similar securities
Based on sector and market capitalization
Report issue